Tag: Targeted

New PET tracer accurately detects common cancer mutations and enables targeted treatment

New PET imaging tracers have been proven to safely and effectively detect common cancer gene mutations, which are important molecular markers for tumor-targeted therapies. Identifying this mutation early allows doctors to tailor treatment plans to patients to achieve the best results. The study was published in the December issue of the journal. nuclear medicine journal. […]

First-in-class targeted therapy has potential for colon cancer

Germany’s Merck KGaA (MRK:DE) announced a licensing agreement with New York-based small molecule developer Inspirna. The agreement is for ompenacrid, a first-in-class SLC6A8 blocker, and will also include other similar follow-on compounds. Omphenacrid is currently being evaluated in a Phase II trial for second-line treatment of certain people with advanced or metastatic colorectal cancer (mCRC). […]

New targeted therapy for colorectal cancer approved in the US

Japanese pharmaceutical giant Takeda Pharmaceutical (TYO: 4502) has received US approval for Fluzakura (fruquintinib), an oral targeted therapy for colorectal cancer. The U.S. Food and Drug Administration’s decision targets the treatment of metastatic colorectal cancer (mCRC) in patients who have already tried other options, such as chemotherapy or anti-VEGF therapy. Fluzacra, an oral and chemotherapy-free […]

Targeted combination therapy triumphs in KRAS-positive metastatic colorectal cancer

MADRID — The combination of a KRAS G12C inhibitor and an EGFR inhibitor significantly improved progression-free survival (PFS) compared to standard of care in patients with chemotherapy-resistant metastatic colorectal cancer (mCRC). was shown in the randomized phase III CodeBreaK 300 trial. With a median follow-up of 7.8 months, median PFS was 5.6 months for patients […]